Publications by authors named "P Faviana"

Objective: Prostate cancer (PCa) is the most common cause of cancer-related deaths in men worldwide. BRCA1/2 genes are reported altered in approximately 1% and 8% of PCa cases, respectively. To date, formalin-fixed paraffin-embedded (FFPE) tissues have a consolidate use in the clinical practice, but with a significant drawback related to DNA/RNA degradation during the pre-analytical process.

View Article and Find Full Text PDF

The impact of tumor microenvironment (TME) in influencing clinical response to first-line immune checkpoint inhibitor (ICI)-based treatment in advanced renal cell carcinoma (RCC) is unclear. Immunohistochemistry (IHC) could identify biomarkers related to immune checkpoints and immune cell population. This study retrospectively characterized TME from 28 RCC patients who received first line ICI-based therapy through IHC assessment of selected markers and explored preliminary evidence about their possible correlation with treatment efficacy.

View Article and Find Full Text PDF

Background: There is little evidence on KRAS mutational profiles in colorectal cancer (CRC) peritoneal metastases (PM). This study aims to determine the prevalence of specific KRAS mutations and their prognostic value in a homogeneous cohort of patients with isolated CRC PM treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Materials And Methods: Data were collected from 13 Italian centers, gathered in a collaborative group of the Italian Society of Surgical Oncology.

View Article and Find Full Text PDF

In 2020, the Global Cancer Observatory estimated the incidence of colorectal cancer (CRC) at around 10.7% coupled with a mortality rate of 9.5%.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of systemic chemotherapy (SC) and its timing in conjunction with surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treating colorectal cancer peritoneal metastases (CRC-PM).
  • Researchers analyzed data from 367 patients across 13 Italian centers, noting different timings for chemotherapy administration: before, after, or both surrounding the CRS-HIPEC procedure.
  • Results indicated that while SC was not linked to an overall survival benefit, receiving SC after the surgery improved disease-free survival rates compared to receiving it before the procedure, highlighting the need for further research on optimal chemotherapy strategies.
View Article and Find Full Text PDF